Lead Product(s) : Inobrodib,Pomalidomide,Dexamethasone
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Pfizer Inc
Deal Size : $25.0 million
Deal Type : Financing
CellCentric Announces $25m Strategic Investment from Pfizer
Details : The company intends to use the net proceeds to fund the development of CCS1477 (inobrodib), its p300/CBP inhibitor to treat specific types of cancer including haematological malignancies and multiple myeloma.
Brand Name : CCS1477
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 11, 2023
Lead Product(s) : Inobrodib,Pomalidomide,Dexamethasone
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Pfizer Inc
Deal Size : $25.0 million
Deal Type : Financing
Lead Product(s) : Inobrodib,Pomalidomide,Dexamethasone
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Inobrodib (CCS1477) is a pioneering drug targeting twin tumour drivers p300/CBP, providing a new way to treat specific cancers, to treat late stage multiple myeloma patients.
Brand Name : CCS1477
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 04, 2022
Lead Product(s) : Inobrodib,Pomalidomide,Dexamethasone
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Inobrodib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : BrightEdge
Deal Size : Undisclosed
Deal Type : Funding
CellCentric Secures Investment from The American Cancer Society’s Impact Venture Capital Fund
Details : The funding will be used to further progress the clinical development of its ground-breaking, targeted treatment, inobrodib (formerly known as CCS1477) and are accompanied by additional significant investment from existing lead investor, Morningside Inve...
Brand Name : CCS1477
Molecule Type : Small molecule
Upfront Cash : Undisclosed
January 26, 2022
Lead Product(s) : Inobrodib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : BrightEdge
Deal Size : Undisclosed
Deal Type : Funding
Lead Product(s) : Inobrodib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Morningside Venture Investments
Deal Size : $33.0 million
Deal Type : Financing
CellCentric Raises $33m to Broaden Clinical Trials of its First-in-Class p300/CBP Inhibitor, CCS1477
Details : CCS1477 is a novel drug in Phase I/II clinical trials to treat late stage prostate cancer, haematological malignancies as well as tumours with p300/CBP mutations. CellCentric plans to investigate CCS1477 both as a monotherapy and in combination with stan...
Brand Name : CCS1477
Molecule Type : Small molecule
Upfront Cash : Undisclosed
October 22, 2020
Lead Product(s) : Inobrodib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Morningside Venture Investments
Deal Size : $33.0 million
Deal Type : Financing
Lead Product(s) : Inobrodib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : CellCentric
Deal Size : Undisclosed
Deal Type : Agreement
Cellcentric Signs Deal for Clinical Trial Expansion into the US
Details : CellCentric has signed an agreement with the Prostate Cancer Clinical Trial Consortium to help select and manage US sites for the ongoing evaluation of CCS1477.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
April 07, 2020
Lead Product(s) : Inobrodib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : CellCentric
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?